This again shows how a good biotech company is destroyed in Aus.
Both of the morons know nothing about the biology/technology behind and dare to make comments on the company and give recommendation.
They do not tell you what is the milestone position of EFTI in NSCLC and HNNSC currently.
They do not tell you there is a bloudy good chance TACTI003 primary target will be met some time this year and this company is in a position of waiting for FDA approval to drop.
They do not tell you the efficacy of treating NSCLC combining with Prembro is the only option to achieve at this level WITHOUT chemo!
The double listing style just opens the door for those wolfy guys in Wall St to play us so hard night by night.
Just wondering of those financial service companies, when can they actually hire a biomedical PhD to analyse a biotech company and/or a engineer PhD to do semiconductor company etc., rather than only reading the numbers for a R&D company.
Overnight Market report, page-1333
-
- There are more pages in this discussion • 1,522 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.005(1.23%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 41.5¢ | 39.5¢ | $1.576M | 3.906M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2506 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 8079 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |